Table 1.
Summary of the most frequently dysregulated miRNA clusters in CRC.
| Cluster | Dysregulation | Function/Role | Related Information | miRNA | Target | Reference |
|---|---|---|---|---|---|---|
| miR-143/145 | Downregulated | Tumor suppressors | Frequently downregulated in CRC due to hypermethylation of their CpG islands. | miR-145 | IRS1 | [84] |
| MUC1 | [85] | |||||
| BRAF and CD44 | [86] | |||||
| IGF1R | [87] | |||||
| KLF5 | [86] | |||||
| MDM2 | [88] | |||||
| MYC | [89] | |||||
| NRAS | [90] | |||||
| FSCN1 | [91] | |||||
| CDCA3 | [92] | |||||
| MAPK1 | [93] | |||||
| SIP1 | [94] | |||||
| catenin δ-1 | [95] | |||||
| YES and STAT1 | [96] | |||||
| PAK4 | [97] | |||||
| ERG | [98] | |||||
| SOX2 | [99] | |||||
| miR-143 | BRAF and CD44 | [86] | ||||
| MDM2 | [88] | |||||
| MYO6 | [100] | |||||
| KRAS | [101] | |||||
| MAPK7 | [102] | |||||
| DNMT3A | [103] | |||||
| HKII | [104] | |||||
| MACC1 | [105] | |||||
| BCL2 | [100] | |||||
| miR-1-2/133a-1, miR-1-1/133a-2, miR-206/133b | Downregulated | Tumor suppressors | myo-miRNAs, muscle-specific miRNAs generally down-regulated in CRC cell lines and tissue samples. | miR-133a | AFTPH | [106] |
| FSCN1 | [107] | |||||
| LASP1 | [108] | |||||
| RFFL | [109] | |||||
| miR-133b | PTBP1 | [110] | ||||
| MET | [111] | |||||
| CXCR4 | [112] | |||||
| miR-206 | NOTCH3 | [113] | ||||
| MET | [114] | |||||
| miR-1 | PTBP1 | [110] | ||||
| NOTCH3 | [115] | |||||
| SMAD3 | [116] | |||||
| miR-497/195 | Downregulated | Tumor suppressors | Expression of miR-497-5p and miR-195-5p is down-regulated in CRC. Increased expression of miR-497-5p or miR-195-5p is associated with decreased cell proliferation, migration and EMT. | miR-497 | IGF1-R | [117] |
| FRA1 | [118] | |||||
| IRS1 | [119] | |||||
| KSR1 | [120] | |||||
| miR-195 | CDK8 | [121] | ||||
| YAP1 | [122] | |||||
| BCL2 | [123] | |||||
| BCL2L2 | [124] | |||||
| γ-catenin | [125] | |||||
| CCNE1 | [126] | |||||
| AXIN2 | [127] | |||||
| miR-15a/16–1,miR-15b/16–2 | Downregulated | Tumor suppressors | Although more frequently miR-15/16 in CRC is detected downregulated, there are also studies documenting up-regulation of miR-15/16 expression. Similarly, better survival is generally correlated with high expression of miR-15/16; however, an association of worse survival with high expression of miR-15/16 has also been documented. | miR-15a | AP4 | [128] |
| GPX4 | [129] | |||||
| SIRT4 | [130] | |||||
| KDM4B | [131] | |||||
| miR-15b | DCLK1 | [132] | ||||
| NF-κB1 and IKK-α | [133] | |||||
| ACOX1 | [134] | |||||
| miR-16 | AP4 | [128] | ||||
| BIRC5 | [135] | |||||
| HMGA2 | [136] | |||||
| ALDH1A3 | [137] | |||||
| COX2 | [138] | |||||
| ITGA2 | [139] | |||||
| miR-192/194–2 and miR-215/194–1 | Downregulated | Tumor suppressors | Frequently downregulated in CRC, the reported functions of miR-192/194-2 and miR-215/194-1 clusters indicate their tumour-suppressive roles as cell cycle arrest and inhibition of cell adhesion are often observed after their overexpression. | miR-192 | CAV1 | [140] |
| EIF5A2 | [141] | |||||
| miR-194 | VAPA | [142] | ||||
| KLK10 | [143] | |||||
| MAP4K4 | [144] | |||||
| THBS1 | [145] | |||||
| PDK1, AKT2 and XIAP | [146] | |||||
| SSH2 | [147] | |||||
| SOX5 | [148] | |||||
| SIRT1 | [149] | |||||
| miR-215 | EREG and HOXB9 | [150] | ||||
| Atg14 | [151] | |||||
| CDX1 | [152] | |||||
| miR-183/96/182 | Upregulated | Oncogenes | Frequently downregulated in CRC, miR-183/96/182 cluster promote migration, invasion and metastasis. | miR-183 | ATG5 | [153] |
| FOXO1 | [154] | |||||
| PFN2 | [155] | |||||
| DNAJB4 | [156] | |||||
| RCN2 | [157] | |||||
| miR-96 | TPM1 | [158] | ||||
| CPA6 | [159] | |||||
| AMPKα2 | [160] | |||||
| TP53INP1, FOXO1, FOXO3a | [161] | |||||
| miR-182 | NAMPT | [162] | ||||
| CFL1 | [163] | |||||
| TIAM1 | [164] | |||||
| DAB2IP | [165] | |||||
| SATB2 | [166] | |||||
| ST6GALNAC2 | [167] | |||||
| FoxF2 | [168] | |||||
| TSP-1 | [169] | |||||
| miR-17/92a | Upregulated | Oncogenes | miRNAs of miR-17/92a cluster can act as oncogenes and promote proliferation, angiogenesis and inhibit differentiation and apoptosis. | miR-17 | HSPB2 | [170] |
| MFN2 | [171] | |||||
| BLNK | [172] | |||||
| RUNX3 | [173] | |||||
| PLCD1 | [174] | |||||
| CADM2 | [175] | |||||
| VEGFA | [176] | |||||
| P130 | [177] | |||||
| VIM | [178] | |||||
| SPOP | [179] | |||||
| PTEN | [180] | |||||
| RND3 | [181] | |||||
| hCNT1 | [182] | |||||
| miR-18a | ING4 | [183] | ||||
| BTG3 | [184] | |||||
| PIAS3 | [185] | |||||
| TBPL1 | [186] | |||||
| miR-19a | PTEN | [187] | ||||
| IREB2 | [188] | |||||
| CLCA4 | [189] | |||||
| THBS1 | [190] | |||||
| KRAS | [191] | |||||
| FOXF2 | [192] | |||||
| NPEPL1 | [193] | |||||
| miR-19b | FBXW7 | [194] | ||||
| PPP2R5E | [195] | |||||
| ACSL1, ACSL4, and SCD | [196] | |||||
| miR-20a | ATG5 and FIP200 | [197] | ||||
| CXCL8 | [198] | |||||
| PDCD4 | [199] | |||||
| MICA | [200] | |||||
| FOXJ2 | [201] | |||||
| PTEN | [202] | |||||
| SMAD4 | [203] | |||||
| miR-92a | DKK3 | [204] | ||||
| SOCS3 | [205] | |||||
| NF2 | [206] | |||||
| KLF4 | [207] | |||||
| miR-200c/141 | Upregulated | Biomarkers | miRNA members of the miR-200c/141 cluster are found to be frequently upregulated in CRC at both tissue and circulating levels. | miR-200c | VLDLR | [208] |
| KIF14 | [209] | |||||
| JNK2 | [210] | |||||
| miR-141 | SIP1 | [211] | ||||
| EGFR | [212] | |||||
| ZEB1 and ZEB2 | [213] | |||||
| MAP4K4 | [214] | |||||
| DLC1 | [215] | |||||
| miR-203a/203b | Upregulated | Biomarkers | miR-203a/203b are generally overexpressed in CRC and are associated with poor prognosis. | miR-203a | PTEN | [216] |
| RNF6 | [217] | |||||
| PDE4D | [218] | |||||
| THBS2 | [219] | |||||
| CREB1 | [220] | |||||
| miR-203b | BCL2L1 | [221] | ||||
| miR-222/221 | Upregulated | Circulating biomarkers | Both members of the miR-222/221 cluster are positively correlated with disease recurrence and are frequently detected upregulated in in the circulation of patients with CRC. | miR-222 | SPINT1 | [222] |
| CD4 | [223] | |||||
| ADAM-17 | [224] | |||||
| MIA3 | [225] | |||||
| ATF3 | [226] | |||||
| BRG1 | [227] | |||||
| MST3 | [228] | |||||
| miR-221 | SPINT1 | [222] | ||||
| CD4 | [223] | |||||
| TP53INP1 | [229] | |||||
| CDKN1C/p57 | [230] | |||||
| SOCS3 | [231] | |||||
| RECK | [232] | |||||
| 23a/27a/24–2 | conflicting data | conflicting data | Members of miR-23a/27a/24-2 cluster has been proposed to control the cell cycle, cell proliferation, cell death and cell differentiation. | miR-23a | SEMA6D | [233] |
| APAF1 | [234] | |||||
| miR-27a | c-Met | [235] | ||||
| BTG2 | [236] | |||||
| RMST | [237] | |||||
| miR-24 | NRP1 | [238] | ||||
| miR-29b-1/29a | Upregulated | Biomarkers | miR-29b-1/29a seems to have a biomarker value for risk, recurrence, metastasis and survival outcome of CRC. | miR-29b-1 | SMAD3 | [239] |
| miR-29a | RPS15A | [240] | ||||
| TNFAIP3 | [241] | |||||
| KLF4 | [242] | |||||
| miR-301b/130b | Upregulated | Oncogenes | Members of the miR-301b/130b cluster act as oncogenes by promoting cell growth and migration and may serve as biomarkers for the diagnosis of CRC. | miR-301b | HOXB1 | [243] |
| miR-130b | CHD9 | [244] | ||||
| integrin α5 | [245] |